BofA lowered the firm's price target on Becton Dickinson to $170 from $177 and keeps a Neutral rating on the shares. Noting that the firm's services team continues to highlight a lower utilization environment, the analyst wants to take a more conservative view on 2027 medtech company estimates given valuations are already reflecting utilization risk, the analyst tells investors. The analyst, who is also assuming inflation is more of a headwind in 2027 with less margin expansion for medtech, lowers 2027 estimates across the firm's larger-cap coverage where there's exposure to utilization and inflation.
